Effect of heparin and enoxaparin in patients undergoing primary angioplasty
Phase 3
Recruiting
- Conditions
- Acute myocardial infarction.ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction
- Registration Number
- IRCT20220809055645N4
- Lead Sponsor
- Rasht University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 171
Inclusion Criteria
Myocardial infarction with ST segment elevation
Exclusion Criteria
Having coagulopathy
Having no consent to participate in the study and follow-up courses
Having underlying bleeding disorders, mechanical valve history
Presence of other indications for receiving anticoagulants
Absolute prohibition of receiving anticoagulants (such as active bleeding at the time of visit, drug sensitivity)
GFR lower than 30
liver failure
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of stroke. Timepoint: 40 days after primary angioplasty. Method of measurement: By using clinical documents of patients and asking them.;Cardiac death. Timepoint: 40 days after primary angioplasty. Method of measurement: By using clinical documents of patients.;Recurrent myocardial infarction. Timepoint: 40 days after primary angioplasty. Method of measurement: By using clinical documents of patients.
- Secondary Outcome Measures
Name Time Method Mean ejection fraction of the left ventricle. Timepoint: 40 days after primary angioplasty. Method of measurement: Echocardiography.